Montelukast Dorom

Montelukast, the active ingredient in Montelukast Dorom, is a leukotriene receptor antagonist presented as a tablet for oral use. It helps control asthma symptoms and allergic rhinitis in adults and children by reducing airway inflammation and nasal congestion.

GNH USA supplies Montelukast Dorom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to manage chronic respiratory and allergic conditions.

Asthma: reduces frequency of wheezing episodes and improves lung function. Allergic rhinitis: alleviates nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Nausea - Fatigue

Serious or Rare Side Effects: - Allergic reactions such as angioedema or anaphylaxis - Neuropsychiatric events including mood changes or suicidal thoughts - Hepatic enzyme elevation - Severe skin reactions such as Stevens‑Johnson syndrome

Before prescribing Montelukast, clinicians should consider several safety aspects. - Liver function monitoring: assess hepatic status in patients with known liver disease. - Neuropsychiatric vigilance: watch for mood changes, depression or suicidal ideation. - Caution in severe hepatic impairment: dose adjustment may be required. - Hypersensitivity: avoid in individuals with known allergy to Montelukast or excipients. - Store at below 25°C: keep in the original pack, protect from moisture.

Montelukast may interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that may lower Montelukast exposure. - Concurrent use with other leukotriene modifiers (e.g., zafirlukast) due to additive pharmacologic activity. - Phenobarbital, which can increase metabolic clearance.

Moderate Interactions (Monitor Closely): - SSRIs or other antidepressants that may heighten neuropsychiatric risk. - Beta‑agonists where combined bronchodilation could enhance effects. - Warfarin, as Montelukast may modestly affect anticoagulant control.